NextCure, Inc. announced the publication of a paper titled Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-ß signaling enables PD-L1-mediated tumor eradication in the Journal of Clinical Investigation. This publication outlines data from a preclinical study on the impact of collagens in the extracellular matrix (ECM) on tumor immune infiltration, immune cell activation and anti-tumor responses. The study investigated the effect of targeting collagens in the tumor microenvironment (TME) that signal through the inhibitory leukocyte-associated immunoglobin-like receptor-1 (LAIR-1) in combination with targeting TGF-ß and programmed cell death ligand 1 (PD-L1) in murine models of cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.44 USD | -5.88% | -4.64% | +26.32% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.32% | 40.28M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.78% | 22.2B | |
-16.53% | 21.23B | |
-9.12% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- NXTC Stock
- News NextCure, Inc.
- NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation